Posts

Showing posts from April, 2018

CureApp and its “Digital Therapeutics”, together with NASH (Non-Alcoholic Steatohepatitis) have launched multi-center clinical trials of their Digital Therapeutics.

Image
CureApp and its “Digital Therapeutics︎︎”, together with NASH (Non-Alcoholic Steatohepatitis)have launched multi-center clinical trials of their Digital Therapeutics.   CureApp Co., Ltd (head office: Chuo-ku, Tokyo, President and CEO: Kohta Satake) in collaboration with Koike Kazuhiko and Assistant Professor Masaya Sato from the Department of Gastroenterology and Internal Medicine at the University of Tokyo Hospital, have been carrying out the research and development of “Digital Therapeutics”. We are pleased to inform you that we are starting multiple institutional clinical trials of the (NASH App) Digital Therapeutics, an application dedicated to the treatment of NASH (Non-Alcoholic Steatohepatitis). This research follows the results of feasibility studies that have been conducted since 2016 at the University of Tokyo Hospital. It is a novel multi institutional clinical research project that has just begun and we aim to continue to obtain evidence to impro

CureApp Satellite Session Present at the 17th World Conference on Tobacco or Health

Image
CureApp Satellite Session Present at the 17th World Conference on Tobacco or Health CAPE TOWN, South Africa ‒   CureApp showcased their breakthrough invention “ Smoking Cessation “ program at the 17th World Conference on Tobacco or Health (WCTOH) in Cape Town, South Africa from March 7-9, 2018. The WCTOH is the premier international forum on tobacco control that aims to foster regional and international partnerships through exchange and mentorship opportunities. This year, for the first time in its 50-year history, the event was held on the African continent. The conference brought together 2000 delegates from more than 100 countries, including researchers, academics, non-governmental organizations, civil society, scientists, healthcare professionals and public officials, working on all aspects of tobacco control. As the conference theme “ Uniting the World for a Tobacco-Free Generation” suggests, international collaboration is vital for

CureApp and HIKARI LAB have began offering the “ascureSPARX Mental Health Program”: A doctor developed application based on cognitive behavior therapy and online counseling.

Image
CureApp and HIKARI LAB have began offering the “ascureSPARX Mental Health Program”: A doctor developed application based on cognitive behavior therapy and online counseling.   CureApp Co., Ltd. (head office: Chuo-ku, Tokyo, President and CEO: Kouta Satake)  which deals with the research and development of “Treatment Applications” as medical  devices in treatment programs, together with HIKARI LAB Co., Ltd. (Head office: Chuo-ku,  Tokyo, President: Ayako Shimizu) which offers online counselling and smart phone  applications for psychological care, have joined together to begin offering the “ascureSPARX  Mental Health Program”: A program designed for corporate mental counselling through the  combination of specialized applications and online remote guidance. The “ascureSPARX Mental Health Program” is a psychological care and counseling program that combines a “doctor developed application” and “online counseling”. It provides psychological care based